We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+7.4%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$471B
AUM Growth
+$12.9B
Cap. Flow
-$11.2B
Cap. Flow %
-2.38%
Top 10 Hldgs %
12.86%
Holding
2,627
New
87
Increased
929
Reduced
999
Closed
89

Top Sells

Rank Stock Value
1
RTX icon
RTX Corp
RTX
+$1.73B
2
ECL icon
Ecolab
ECL
+$1.17B
3
CCI icon
Crown Castle
CCI
+$906M
4
PSX icon
Phillips 66
PSX
+$775M
5
GILD icon
Gilead Sciences
GILD
+$756M

Sector Composition

Rank Sector Weight
1 Healthcare 19.84%
2 Consumer Discretionary 13.93%
3 Financials 13.41%
4 Industrials 12.4%
5 Technology 9.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EXTR icon
2326
Extreme Networks
EXTR
$3.2B
$208K ﹤0.01%
59,000
HHS icon
2327
Harte-Hanks
HHS
$18.6M
$207K ﹤0.01%
2,675
ATLO icon
2328
AMES National
ATLO
$281M
$206K ﹤0.01%
+7,950
New +$193K
SRPT icon
2329
Sarepta Therapeutics
SRPT
$1.94B
$205K ﹤0.01%
14,148
UHT
2330
Universal Health Realty Income Trust
UHT
$573M
$205K ﹤0.01%
+4,250
New +$200K
MCBC
2331
DELISTED
Macatawa Bank Corp
MCBC
$205K ﹤0.01%
37,700
+600
+2% +$3.1K
GTN icon
2332
Gray Television
GTN
$498M
$204K ﹤0.01%
18,200
IMGN
2333
DELISTED
Immunogen Inc
IMGN
$204K ﹤0.01%
33,413
+3,213
+11% +$29.4K
PCTI
2334
DELISTED
PCTEL, Inc. Common Stock
PCTI
$204K ﹤0.01%
23,600
MCEP
2335
DELISTED
Mid-Con Energy Partners, LP
MCEP
$204K ﹤0.01%
1,620
-1,840
-53% -$516K
MLCO icon
2336
Melco Resorts & Entertainment
MLCO
$2.14B
$203K ﹤0.01%
8,000
SFNC icon
2337
Simmons First National
SFNC
$3.45B
$203K ﹤0.01%
+10,000
New +$201K
BMS
2338
DELISTED
Bemis
BMS
$203K ﹤0.01%
4,500
-159,284
-97% -$6.42M
OCRX
2339
DELISTED
Ocera Therapeutics, Inc.
OCRX
$203K ﹤0.01%
31,942
-500
-2% -$2.92K
UVSP icon
2340
Univest Financial
UVSP
$1.18B
$202K ﹤0.01%
10,000
KWR icon
2341
Quaker Houghton
KWR
$2.91B
$201K ﹤0.01%
+2,182
New +$176K
DTSI
2342
DELISTED
DTS, Inc.
DTSI
$201K ﹤0.01%
+6,522
New +$196K
CCO icon
2343
Clear Channel Outdoor Holdings
CCO
$1.23B
$200K ﹤0.01%
18,900
WNEB icon
2344
Western New England Bancorp
WNEB
$282M
$200K ﹤0.01%
27,200
-1,000
-4% -$7.18K
VWTR
2345
DELISTED
Vidler Water Resouces, Inc. Common Stock
VWTR
$200K ﹤0.01%
10,600
GLBR
2346
DELISTED
Global Brokerage, Inc. Class A Common Stock
GLBR
$200K ﹤0.01%
1,210
ARO
2347
DELISTED
Aeropostale Inc
ARO
$199K ﹤0.01%
85,700
+28,600
+50% +$81.3K
JRN
2348
DELISTED
JOURNAL COMMUNICATIONS INC CL-A
JRN
$199K ﹤0.01%
17,400
NFBK
2349
DELISTED
Northfield Bancorp
NFBK
$198K ﹤0.01%
13,400
VICR icon
2350
Vicor
VICR
$10.4B
$198K ﹤0.01%
16,400

Similar funds

T. Rowe Price Associates's Q4 2014 Portfolio in Review

As of Q4 2014, T. Rowe Price Associates held 2,627 positions worth $471B, up 2.8% from $458B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

T. Rowe Price Associates's Q4 2014 filing shows 87 new, 929 increased, 999 reduced and 89 closed positions. Its largest new stake was Keysight: 17,553,953 shares worth $593M. The largest sale was RTX Corp, an estimated $1.73B.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Financials.

  • T. Rowe Price Associates's largest Q4 2014 buy was Keysight: 17,553,953 shares worth $593M.
  • T. Rowe Price Associates added most to Allergan plc in Q4 2014, an estimated $1.66B increase.
  • T. Rowe Price Associates's biggest Q4 2014 reduction was RTX Corp, cutting an estimated $1.73B.
  • T. Rowe Price Associates fully exited ATHLON ENERGY INC COM in Q4 2014, selling an estimated $499M.
  • T. Rowe Price Associates's ten largest holdings make up 13% of its $471B portfolio in Q4 2014.
  • T. Rowe Price Associates opened 87 new positions and closed 89 in Q4 2014.
  • T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $471B.

Based on T. Rowe Price Associates's 13F filing for Q4 2014, filed 13 Feb 2015.